Prescription drug · ANDA
Deferasirox NDC 62332-326
Deferasirox 500 mg/1 · Tablet, For suspension · Oral · Alembic Pharmaceuticals Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 62332-326-30 | 62332032630 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (62332-326-30)Marketed from Nov 21, 2019 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Deferasirox
- Generic name (nonproprietary)
- deferasirox
- Active ingredients
- Deferasirox — 500 mg/1
- Dosage form
- Tablet, For suspension
- Route
- Oral
- Labeler
- Alembic Pharmaceuticals Inc.
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 210060
- Marketing start
- Listing expires
- Other FDA classes
- Cytochrome P450 1A2 Inhibitors (Mechanism)Cytochrome P450 2C8 Inhibitors (Mechanism)Cytochrome P450 3A4 Inducers (Mechanism)Iron Chelating Activity (Mechanism)
- Identifiers
- Product ID 62332-326_d58faf4c-c55c-47fc-928a-f56e8240a85cSPL ID d58faf4c-c55c-47fc-928a-f56e8240a85cSPL set ID 1f9f1a69-bf71-4e6a-88b0-90f08c4da79fRxCUI 597768, 597770, 597772UNII V8G4MOF2V9UPC 0362332326303
- Pharmacologic class
- Iron Chelator
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N462332032630followed by a unit qualifier and the quantityPackage 62332-0326-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
Deferasirox tablets for oral suspension are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. (1.1) Deferasirox tablets for oral suspension is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L. (1.2) Limitations of Use: The safety and efficacy of deferasirox tablets for oral suspension when administered with other iron chelation therapy have not been established. (1.3) 1.1 Trea…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 210060
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Deferasirox | Deferasirox 125 mg/1 | Tablet, For suspensionOral | Alembic Pharmaceuticals Limited | 46708-324 |
| Deferasirox | Deferasirox 250 mg/1 | Tablet, For suspensionOral | Alembic Pharmaceuticals Limited | 46708-325 |
| Deferasirox | Deferasirox 500 mg/1 | Tablet, For suspensionOral | Alembic Pharmaceuticals Limited | 46708-326 |
| Deferasirox | Deferasirox 250 mg/1 | Tablet, For suspensionOral | Alembic Pharmaceuticals Inc. | 62332-325 |
| Deferasirox | Deferasirox 125 mg/1 | Tablet, For suspensionOral | Alembic Pharmaceuticals Inc. | 62332-324 |